New Test Identifies Breast Cancer Patients Who Can Avoid Surgery

Got story updates? Submit your updates here. ›

A new diagnostic test called SignateraTM MRD has been shown to accurately identify breast cancer patients who can safely avoid undergoing surgery. The test looks for minimal residual disease (MRD) - the presence of small amounts of cancer cells that remain after initial treatment - to determine if a patient is likely to relapse or if they can forgo more invasive procedures like mastectomy or lumpectomy.

Why it matters

This breakthrough could significantly improve quality of life for many breast cancer patients by allowing them to avoid the physical and emotional toll of surgery. It also has the potential to reduce healthcare costs associated with unnecessary procedures. The test represents an important advancement in personalized, precision oncology.

The details

The SignateraTM MRD test analyzes blood samples to detect the presence of cancer cells that may have survived initial treatment. Patients with no detectable MRD are considered at very low risk of relapse, meaning they may be able to safely skip surgery and instead continue with less invasive treatments like radiation or hormone therapy. Clinical trials have shown the test to be highly accurate in predicting which patients can forgo surgery without compromising their outcomes.

• The SignateraTM MRD test was developed and validated through clinical studies over the past several years.
• The test received regulatory approval and became commercially available in March 2026.

What they’re saying

What’s next

Larger clinical studies are planned to further validate the SignateraTM MRD test's accuracy and applicability across different breast cancer subtypes and stages. If the results continue to be positive, the test could become a standard part of breast cancer care, helping many patients avoid the burdens of surgery.